Regenexx is a U.S. company specializing in orthopedic applications of stem cells that was founded by Dr. Chris Centeno. Dr. Centeno is an international expert in regenerative medicine and the clinical use of mesenchymal stem cells (MSCs) in orthopedic applications. His Regenexx clinic in Denver, Colorado, incorporates a variety of regenerative approaches, drawing patients from all over the U.S. who are seeking innovative, non-surgical treatments. [Read more…]
Today, exosomes are increasingly being investigated as a novel class of therapeutics that could explain the functions of many types of traditional cell therapies. To explain this trend, we contacted an esteemed exosome researcher, Dr. Ramon Coronado Schmilinski. Dr. Coronado Schmilinski was the previous Executive Director at Lester Smith Medical Research Institute and is the current VP Regulatory Affairs and Technology Transfer at Signature Biologics.
In this interview, we discuss how he started working with exosomes while looking for mechanisms used by MSCs to exert their therapeutic effects. We discuss the scientific importance of exosomes, their therapeutic and diagnostic applications, and how exosomes are being used within encapsulation and delivery systems.
Read on to learn how these extracellular vesicles could transform the future of modern medicine as we know it.
In this interview with David Sheehan (CEO), we explore how Nucleus Biologics is revolutionizing the cell culture market through a concept known as “Precision Cell Culture.” The focus of Nucleus Biologics is to deliver superior cell culture products by leveraging a transparent, consistent and proven supply chain that eliminates variability for its customers. In addition to its novel Physiologix™ product line, Nucleus Biologics provides the highest quality Australia and New Zealand origin fetal bovine serum (FBS) available in the market with a goal to enable better lifesaving science.
With an estimated $28 billion lost per year to irreproducible biology research, it is clear that the market is overdue for disruption and Nucleus Biologics appears to be the company positioned to do it. In this interview, we explore Mr. Sheehan’s background, the disruptive nature of Nucleus Biologics, and his inspiring vision for the future. [Read more…]
Stemmatters is a Portuguese contract development and manufacturing (CDMO) organisation based in Barco, Guimarães. Originally a spin-off from University of Minho, it offers contract development and manufacturing services for cell-based advanced therapies, exosomes, blood-derived biologics, tissue products, biomaterials, and combination devices.
In the interview below, we explore Stemmatters history, services, manufacturing facilities, and future goals. Enjoy! [Read more…]
In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.
The pace never slows when your mission is to enable lifesaving science! [Read more…]